Thank you for participating!

Thank you to all who contributed to the National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning Forum. Ultimately, over 1,000 ideas were submitted, with more than 42,000 votes. This remarkable response exceeded expectations and provided a wealth of ideas to draw upon as NHLBI moves forward. Please visit the NHLBI Strategic Visioning page to find out more about the NHLBI Strategic Visioning process.


Welcome to the National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning Forum. The Institute is gathering ideas for the most compelling scientific priorities in the four NHLBI Strategic Goals to address over the next decade.

(@jantin)

Goal 3: Advance Translational Research

Can SYK or BTK inhibition ameliorate autoimmune hemolytic anemia after stem cell transplantation

Experimental mouse models of ITP and AIHA are dependent on FcgR-signaling, which in turn depends on Syk kinase activity for activation of phagocytes. A significant and refractory complication of stem cell transplantation is immune hemolytic anemia. This can be either autoimmune or alloimmune. In either case it is likely that clearance of RBC and RBC progenitors is dependent on extravascular mechanisms involving activation ...more »

Voting

23 net votes
52 up votes
29 down votes
Active
(@nhlbiforumadministrator)

Goal 4: Develop Workforce and Resources

Education in glycobiology is nearly non-existent

Aside from a handful of locations around the country, there are no local opportunities for the vast majority of PhD students to learn about glycobiology. A search on NIH Reporter for T32 grants with "glycobiology” reveals two grants (one NCI for cancer cell biology, one NIGMS for pharmacology). Neither of these grants are focused upon glycobiology. In fact, glycobiology is essentially never integrated into any standard ...more »

Voting

2 net votes
2 up votes
0 down votes
Active
(@gerald.bloomfield)

Goal 2: Reduce Human Disease

Team Science in Global Health: Reducing the Burden of Chronic Heart, Lung, Blood Disorders in Developing Countries

By 2025, the world we will either meet or fall short of the goal to reduce the burden of chronic diseases globally by 25% by 2025. Most of this disease burden occurs in developing countries. Multi-disciplinary, multi-national partnerships to combat chronic heart, lung and blood disorders are needed for the most resolute, effective and sustainable responses. We need a program of research that addresses the highly variable ...more »

Voting

4 net votes
17 up votes
13 down votes
Active
(@nhlbiforumadministrator)

Goal 1: Promote Human Health

Human normal variation and resilience across lifespan

What is the measureable normal human variation at the -omic, cellular, organ, and system levels within the population and across the lifespan? • What are the range of normal human cellular functions that create resilience at all levels—cells, organs, organ systems? • What inter-organ, tissue, and cellular communications maintain individual health and the health of populations? • How do we understand why individuals with ...more »

Voting

19 net votes
26 up votes
7 down votes
Active
(@katherinek)

Goal 2: Reduce Human Disease

How can we increase the pharmaceutical clinical research of targeted therapies in pediatric PAH patients, including encouraging

Clinical research, especially randomized pharmaceutical clinical trials, poses many unique challenges compared to research in adult subjects. In pulmonary arterial hypertension, a disease characterized by high blood pressure of the lungs with increased pulmonary vascular resistance leading to right ventricular failure, there are 12 FDA-approved PAH-targeted therapies for adults. None of these medications are currently ...more »

Voting

66 net votes
76 up votes
10 down votes
Active
(@bldbuddy)

Goal 2: Reduce Human Disease

What new methods of platelet preparation, processing, and storage are needed for hemostasis in various clinical conditions?

The limitations of 5-day 22˚ C storage significantly impacts platelet availability. It is critical that we develop new methods of collection, processing, storage to extend the storage time of platelets, and evaluate the use of whole blood. The attributes of these products must be understood to optimally alignment product attributes, clinical efficacy and safety with hemostatic needs in a variety of clinical states. Specifically, ...more »

Voting

14 net votes
34 up votes
20 down votes
Active
(@nhlbiforumadministrator1)

Goal 3: Advance Translational Research

Natural Experiments and Obesity

How can approaches, such as natural experiments, be used to capture the evolution and impact of policies/environmental change that are related to obesity? There needs to be a mechanism that can quickly support the funding of natural experiment research. For instance, NIDDK and NICHD participate in a rapid response PAR that funds natural experiments in a timely manner. It only takes about 4 months from when the application ...more »

Voting

32 net votes
62 up votes
30 down votes
Active
(@nhlbiforumadministrator1)

Goal 2: Reduce Human Disease

Clinical Research for HIV/AIDS and HLB Health and Diseases

What HIV/AIDS-related clinical research can NHLBI support in the next 5-10 years on the prevention, diagnosis, and treatment of HIV-related heart, lung, and/or blood (HLB) diseases in adults and children to improve heart, lung, and blood health outcomes in HIV infections?

Voting

-19 net votes
14 up votes
33 down votes
Active